The Board of Atlas Antibodies and Nille Klaebel have together agreed that Nille will leave her position as the CEO of Atlas Antibodies Group. Peter Ulvskjold, currently CEO of the division Atlas Antibodies, will assume the role as interim CEO for the Group, as of February 1st.
Åsa Riisberg, professional board member and former partner of EQT AB, has been appointed new Chair of the Board of Patricia Industries' wholly owned subsidiary Atlas Antibodies, a leading fast-growing provider of innovative and high-quality antibodies and recombinant antibody expressions to researchers around the world. Åsa Riisberg will succeed Torben Jørgensen, who leaves the Board, effective January 1, 2023.
Atlas Antibodies is pleased to announce Peter Ulvskjold as the new CEO with effect from the 1st of October 2022.
Peter Ulvskjold joined Atlas Antibodies from his role as Chief Transformation Officer at ConvaTec.
Our company has now released new PrecisA MonoclonalTM antibodies targeting 23 proteins relevant to ovarian cancers, with diagnostic and prognostic values validated in IHC, WB and ICC-IF.
MolBoolean is expected to be a valuable tool for researchers studying protein activity in cells and tissue and, in the long term, be used in healthcare to improve diagnosis and choice of treatment for cancer. Atlas Antibodies recently overtook the patent for MolBoolean and is now preparing the method for the market.
What a great beginning of the summer for our company in Paris at #FENS2022, the largest European international gathering for neuroscientists.
We are happy to announce that Chiara Musillo, a Ph.D. student from La Sapienza University of Rome, Italy, is the recipient of the Atlas Antibodies’ travel grant of 500 euros to attend the FENS Forum 2022 in Paris, 9-13 July.
The Swedish biotech company Atlas Antibodies lands its best annual results to date. Strategic acquisitions and a progressive business plan have paved the way for organic growth above 30 pct. and a nearly three-fold increase in revenue. Danish CEO Nille Klæbel is persistently on the lookout for more companies to add to the Atlas Antibodies family of protein-centric businesses.
Dr. Caroline Kampf, Chief Scientific Officer at Atlas Antibodies, gave an interview for our new distributor Biomol from Germany. She talked about the history of our company, the high specificity of our polyclonal antibodies, applications for the customers and much more…
We are happy to announce the release of 1,200 new Triple A Polyclonals™. Atlas Antibodies now offers over 22,000 highly validated primary antibodies for tissue and cell analysis.
We continuously expand our portfolio of cancer research related products. Our latest set of mouse monoclonals focuses on markers for glioma and neuroendocrine tumors.
T-Cure Biosciences, Inc. and Atlas Antibodies AB have entered a collaboration agreement for the development, manufacture, and supply of CT83 (KK-LC-1) monoclonal antibodies for diagnostic use.
Atlas Antibodies is pleased to announce Nille Klæbel as the new CEO with effect from 15 September 2021.
“We are delighted to welcome Nille as the new CEO of Atlas Antibodies” says Torben Jørgensen, chairman of the Board of Directors and continues: “With her strong background in marketing and sales and knowledge of the life sciences, pharma and healthcare industries, Nille is highly equipped to lead the next important steps in the development of Atlas Antibodies into a global life sciences company.”
Atlas Antibodies is pleased to announce it has received ISO 9001:2015 certification. ISO 9001 is the internationally recognized standard for a quality management system (QMS) and organizations adhere to the standard to organize and continually improve business processes and efficiency.
Stockholm / Zürich, July 28, 2021
Stockholm / Newcastle upon Tyne, February 15, 2021
QPrEST+ is an extension of our QPrEST™ product line for targeted proteomics
Don’t miss our webinar today on QPrEST™ standards for absolute quantification using mass spectrometry.
We are delighted to release 50 new PrecisA Monoclonals focusing on protein targets for cancer research, including markers for cancer processes and different tumor types.
Register today for our free webinar "Quantitative Analysis of Plasma Proteins by Targeted Mass Spectrometry”, held on February 25, 2020.
Fundamental to the success of a Western blot procedure is the ability of the primary antibody to detect the protein of interest. But how to validate an antibody for Western blot? Read our latest blog post to find out.
Proteins of the same length or similar size such as isoforms of the same protein, are difficult to separate using the Western blot application. With some adjustments you can however achieve great results. In today's blog post we share our best tips.
We wish to extend a sincere thank you to all our customers and partners in 2019. It has been a pleasure to work with you and we look forward to 2020!
We also would like to take this opportunity to inform about our shipping and business hours during the holidays.
The ASCB/EMBO meeting starts this weekend in Washington DC and we hope to see you there.
We will be joined by scientists from the Human Protein Atlas, and we are all looking forward to giving you a demo of the Cell Atlas. Come by our booths #425 and #427.
In today's blog post, we interview Dr. Peter Thul, group leader at the Human Protein Atlas (HPA) project, Stockholm, Sweden. Dr. Thul is one of the scientists behind the Cell Atlas: a database that provides high-resolution insights into the expression and spatio-temporal distribution of proteins within human cells. We asked Peter 10 questions about the past, the present, and the future of the Cell Atlas.
The webinar "The Brain Atlas: A road map through the complex protein signature of the brain" is held today at 12 pm ET, hosted by AAAS/Science.
Professor Mathias Uhlén and Dr. Evelina Sjöstedt from the Human Protein Altas will give you an introduction to the new Brain Atlas section of the Human Protein Atlas and to the research behind it.
Register today at the AAAS/Science website.
In today's blog post, we share our favorite highlights from the Annual Society for Neuroscience (SfN) meeting last month. The SfN meeting features the latest discoveries in brain research, from the basic mechanisms, to translational and clinical studies. This year, the conference celebrated its 50th anniversary in the “Windy City”, Chicago, IL, USA. Unsurprisingly, this convention attracted close to 30,000 delegates around the workings of the brain “the universe between your ears” unassuming, but possibly, the most complex structure of the universe.
Read our blog post to learn about the research we found most exciting at the meeting.
In collaboration with Science/AAAS, we're introducing the webinar "The Brain Atlas: A road map through the complex protein signature of the brain", to be held on November 20. Register today to learn about the research behind the Brain Atlas from Human Protein Atlas scientists.
In today's blog post, we interview Dr. Jan Mulder, group leader of the Fluorescence Tissue Profiling facility at Karolinska Institutet, Sweden. Dr. Mulder is the director of the Brain Atlas, the latest addition to the Human Protein Atlas database. We asked Dr. Mulder 10 questions about the past, the present, and the future of the Brain Atlas.
We hope to meet you at SFN in Chicago later this week!
Come by our booth and tell us about your research and let us know what we can offer to help. We will be joined by scientists from the Human Protein Atlas, and we are all looking forward to giving you a demo of the Brain Atlas, the latest addition to the Human Protein Atlas.
The Brain Atlas one of the latest additions to the Human Protein Atlas database, bringing human brain mapping to a new level.
Do you know how many buffers can affect you IHC staining? In our latest blog post, we offer 10 essential tips on how to choose and prepare buffers for IHC.
Atlas Antibodies Presents QPrEST Standards for Absolute Quantification of Proteins using Mass Spectrometry
STOCKHOLM, Sweden, September 15, 2019. Atlas Antibodies AB, a leading supplier of advanced research reagents, announced today the introduction of pre-quantified QPrEST™ Protein Standards for absolute quantification of proteins in biological samples such as cell lysate and plasma using liquid chromatography (LC)–mass spectrometry (MS).
The human body is the results of trillion of cells communicating with each other. Early biologists described cells as simple membranous sacs containing fluid and a few floating particles. Today we know that cells are infinitely more complex than that. In our latest blog, you can learn about the Cell Atlas, part of the Human Protein Atlas, for insights into the spatio-temporal distribution of proteins within human cells. Discover how you can use the Cell Atlas in our research.
As a rule, the complex biology and spatial organization of tissues and solid tumors pose a scientific and diagnostic challenge that is not sufficiently well addressed by standard immunohistochemistry (IHC) procedures. How come this is the case? The answer is that single IHC staining provides data on only one marker at a time. So, how do you stain multiple proteins in the same cell or tissue? Learn more in our latest blog.
Next week, we will be at the ISSCR 2019 Annual Meeting in Los Angeles, CA, USA. If you are planning to attend the meeting, make sure to visit our booth, #1027. We look forward to meeting you and to hear about your research! We're also happy to give you a demonstration on how to use the Human Protein Atlas and present our antibodies for stem cell research.
n our latest blog post, we share the story from when Human Protein Atlas scientists were contacted by another research team with a question and a problem. This lead to a collaboration and published paper on a potential drug target for diabetes type II.
Read our case study and find out how the Human Protein Atlas was used in the study.
Multiplex IHC is a powerful investigative tool which allows for the simultaneous visualization of multiple proteins on a single section by using a specific antibody for each protein of interest. In our latest blog series "Interview with a Scientist", we investigate the past, present and future challenges of multiplex IHC.
Can you make use of an antibody that targets a human protein in another model organism? Under the right conditions, the answer is yes! There are a few things you need to consider before you start. Learn more in our new blog.
Interested in stem cells? Whether you are working in the field are simply interested in learning about different types of stem cells, download and read our two new white papers.
Now you can read the second part of our multi-chapter guide to succeeding with your IHC. This time, the focus is on antigen retrieval.
The antigen retrieval step can be the key to succeeding with your IHC experiment. Sample fixation in IHC can lead to protein cross-linking, which masks antigens limiting the antigen-antibody binding. Antigen retrieval is the technique in which the masking of an epitope is reversed, and epitope-antibody binding is restored. Read our blog to learn all about antigen retrieval.
Now you can read the first part of our multi-chapter guide to succeeding with your IHC.
In part I, we'll share our best advice on tissue processing and handling. The most common cause of poor immunostaining is not the technique itself but the potential influence on the antigenic sites during tissue preparation. The quality of the staining, resulting from the antibody-antigen binding, is to a degree affected by alterations during tissue handling and tissue processing. Some proteins are most susceptible to changes in fixation than others. Read our blog to learn how to make sure you get the most out of your tissue samples.
Atlas Antibodies will be exhibiting at the AACR meeting in Atlanta, March 29 - April 3. Visit us in booth 3245 and get a demo of the Human Protein Atlas and the Pathology Altas. We're looking forward to hearing about your research and discuss what we can offer for your cancer research needs.
An IHC experiment is a combination of three major elements: the sample, the application that is used and the experimental protocol. An excellent IHC staining is achieved when all the required elements, qualities and characteristics are matched perfectly. What if your experiment does not turn out as you planned? If you are looking for suspects to blame for artifacts in your IHC experiment, the three usual suspects are the sample, the antibodies and the protocol.
In our latest blog post, we explain how you can identify which of the suspects are causing problems in your staining and what to do about it.
Join us at Neuroscience 2019, an online conference hosted by Labroots. The conference starts today at 2 pm CET/ 6 am PT. Listen to great talks, check out posters and find us and other companies in the exhibition hall. Registration is free and no travel is needed. We hope to see you there! You can also access the conference content on demand after the live dates.
Cancer is a collection of related diseases in which some of the body’s cells begin to divide without stopping and spread into surrounding tissues. There are at least 200 forms of cancer, and many more subtypes. Different cancers can require different treatments, like chemotherapy, radiation therapy, or immunotherapy. But how do cancers differ in types? How is the same cancer different among individuals?
Our latest blog post explores the Pathology Atlas, an open-access database part of the Human Protein Atlas with the scope of identifying the role of genes, RNA, proteins, and metabolites in the complex human cancerous tissues and organs.
Read the blog to discover how the Pathology Atlas allow pathologists to improve testing methods to predict and find new treatments to fight cancer.
At Atlas Antibodies we are proud to sponsor the 9th Alpbach Workshop on Affinity Proteomics to be held on March 11-13 in Austria.
The Alpbach workshop is regarded as one of the best meetings on antibodies and other protein-binding molecules and their role in defining the proteome. We look forward to presenting our efforts into antibody validation at the meeting and how Enhanced Validation ensures reliable research results.
Today we are delighted to introduce a new PrecisA Monoclonal targeting TMEM119.
TMEM119 (Transmembrane Protein 119) is a useful marker for studying microglia. An advantage over other microglial markers is that TMEM119 is specific for microglia, and not expressed by macrophages.
Our mouse monoclonal Anti-TMEM119 Antibody (AMAb91528) is validated for IHC, WB and ICC-IF. The target specificity of the Anti-TMEM119 antibody has been confirmed using orthogonal enhanced validation, by analyzing the relative expression of the target protein in different samples using both IHC and transcriptomics.
How much time do you spend making a decision for the right control for your primary antibody? And how do you know if you make the right choice?
Primary antibody controls are used to verify the specificity of the primary antibody binding to the antigen of interest. Also, controls for the primary antibody are applied to confirm the correctness of the preanalytical IHC phase related to sample preparation, such as fixation, post fixation, storage, and processing. It is important to include these controls for each new antibody, protocol, and application that you test.
Read our new blog post to learn how to control your IHC by choosing the right primary antibody controls. Don’t forget to subscribe to the blog to never miss a new post.
In science, experimental controls eliminate alternative explanations of experimental results. In IHC, controls are necessary for the validation of staining results.
But how do you select the proper controls? The task to select and apply the correct controls is not easy. Selection of appropriate controls is not purely a technical issue. It requires in-depth knowledge of how the test will be used.
In our new blog post, we help you on your way to figuring out which controls to use in your experiment,
A fundamental part of studying and understanding human biology is the study of tissue-specific gene expression and protein levels. Tissue-specific gene expression can result in the presence or absence of a certain protein, leading to the profound functional variation of biological processes among tissues. This means, the knowledge of protein profiles in a given tissue is critical to understanding the unique characteristics of the various cell types and their functions in the human body.
The expression of all protein-coding genes in all major tissues and organs in the human body can be explored in the Human Protein Atlas, an interactive database, which includes a catalog of proteins expressed in a tissue-oriented manner.
Our new blog post is here to help you on your way to discovering the potential of the Human Protein Atlas.
Choosing a highly validated antibody with premium quality is an essential starting point to drive your results in the desired direction. It is important to choose an antibody that can be trusted, that is reproducible, and that work in specific tissue-application combination you plan to use. Even a good antibody can fail if used in the wrong context. So, if you do have a choice, look for an antibody you can trust and increase your chances of success. But how can you know if you can trust an antibody? Read our new blog post to find out.
We are looking forward to seeing you in 2019!
Our conference schedule is updated with new meetings and conferences, and we hope to have the opportunity to meet you during the year. Atlas Antibodies will exhibit at the AACR, ISSCR, HUPO, SFN meetings and several more international conferences during 2019. If you are planning to attend any of these events we hope to see you in our booth.